News | July 01, 2021
Zydus applies to the DCGI for EUA to launch ZyCoV-D
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
The company is doubling its chemistry research capacity that should commission by Q2'FY22
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Subscribe To Our Newsletter & Stay Updated
